Beta Bionics, a medical technology company, developed the iLet Bionic Pancreas for people with type 1 diabetes. It is an automated system that can deliver insulin in one or two hormone modes, automatically calculating and administering all insulin doses needed. The FDA-approved iLet Bionic Pancreas eliminates traditional setup, carbohydrate counting, correction, and bolus calculation.
The system is compatible with two continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM. It is a pocket-sized, wearable medical device that uses ML algorithms to control blood sugar levels in people with diabetes. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a dual-hormone bionic pancreas.
Key customers and partnerships
The company has collaborated with pharmaceutical companies to improve its lead technology: Zealand Pharma (June 2016) to develop a new dual-hormonal artificial pancreas system for the treatment of diabetes and ConvaTec (July 2019) to manufacture infusion sets for use with Beta Bionics' iLet Bionic Pancreas System, which autonomously controls blood sugar levels in people with diabetes.
Funding and financials
In August 2023, the company raised USD 100 million in Series D funding co-led by Sands Capital and Omega Funds to expand access to the iLet Bionic Pancreas across the US and further develop and test the bi-hormonal bionic pancreas.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.